Pregabalin, commonly referred to as Lyrica®, is a well-known anticonvulsant medication, which has found its footing in the treatment of various medical conditions. Such conditions include but are not limited to anxiety disorders, epilepsy, and neuralgia. The mechanism of action that characterizes pregabalin's utility involves blocking the CACNA2D1 and CACNA2D2 calcium channels, thus effectively targeting these disorders with aplomb. The Upjohn Co. received approval for the medical use of pregabalin in the European Union as far back as 2004, indicating that the medication has been a key feature of medical treatment for some time. Pregabalin's indications primarily target the treatment of neuropathic pain conditions, including fibromyalgia, and partial onset seizures in combination with other anticonvulsant medications. These conditions are managed with pregabalin due to its efficacy in minimizing their attendant symptoms. Pregabalin, therefore, serves as a vital tool in the management of chronic pain and neurological disorders. Click on the image below to begin the exploration journey of Pregabalin through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!